EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors

Émilie Lavallée, Maëline Roulet-Matton, Viviane Giang, Roxana Cardona Hurtado, Dominic Chaput iD, Simon-Pierre Gravel iD

Life Science Alliance · 2025

DOI: 10.26508/lsa.202402912 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Science Alliance, 2025. Verfasst von Émilie Lavallée und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculté de Pharmacie, Université de Montréal, Montréal, Canada. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Polo-Like Kinase 1, Proto-Oncogene Proteins, Cell Cycle Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research Society, Canadian Government | Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PLK1 inhibitors are emerging anticancer agents that are being tested as monotherapy and combination therapies for various cancers. Although PLK1 inhibition in experimental models has shown potent antitumor effects, translation to the clinic has been hampered by low antitumor activity and tumor relapse. Here, we report the identification of mitochondrial protein signatures that determine the sensitivity to approaches targeting PLK1 in human melanoma cell lines. In response to PLK1 inhibition or gene silencing, resistant cells adopt a pro-inflammatory and dedifferentiated phenotype, whereas sensitive cells undergo apoptosis. Mitochondrial DNA depletion and silencing of the ABCD1 transporter sensitize cells to PLK1 inhibition and attenuate the associated pro-inflammatory response. We also found that nonselective inhibitors of the p90 ribosomal S6 kinase (RSK) exert their antiproliferative and pro-inflammatory effects via PLK1 inhibition. Specific inhibition of RSK, on the other hand, is anti-inflammatory and promotes a program of antigen presentation. This study reveals the overlooked effects of PLK1 on phenotype switching and suggests that mitochondrial precision medicine can help improve the response to targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesPolo-Like Kinase 1Proto-Oncogene ProteinsCell Cycle ProteinsMitochondriaApoptosisPhenotypeProtein Kinase InhibitorsHumansCell Line, TumorMelanomaCell ProliferationRibosomal Protein S6 Kinases, 90-kDaAntineoplastic Agents

Substanzen

Protein Serine-Threonine KinasesPolo-Like Kinase 1Proto-Oncogene ProteinsCell Cycle ProteinsProtein Kinase InhibitorsRibosomal Protein S6 Kinases, 90-kDaAntineoplastic Agents

Autor:innen und Institutionen

  • Faculté de Pharmacie, Université de Montréal, Montréal, Canada.
  • Faculté de Pharmacie, Université de Montréal, Montréal, Canada sp.gravel@umontreal.ca.

ORCID-Profile: Dominic Chaput, Simon-Pierre Gravel

Förderung

  • Cancer Research Society
  • Canadian Government | Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Lavallée, É., Roulet-Matton, M., Giang, V., Cardona Hurtado, R., Chaput, D., & Gravel, S. P. (2025). Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors. Life Science Alliance. https://doi.org/10.26508/lsa.202402912

Vancouver

Lavallée É, Roulet-Matton M, Giang V, Cardona Hurtado R, Chaput D, Gravel SP. Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors. Life Science Alliance. 2025. doi:10.26508/lsa.202402912

BibTeX
@article{Lavalle2025,
  author = {Lavallée, Émilie and Roulet-Matton, Maëline and Giang, Viviane and Cardona Hurtado, Roxana and Chaput, Dominic and Gravel, Simon-Pierre},
  title = {Mitochondrial signatures shape phenotype switching and apoptosis in response to PLK1 inhibitors},
  journal = {Life Science Alliance},
  year = {2025},
  doi = {10.26508/lsa.202402912}
}
Kostenlos starten →